New Generation Vaccines
eBook - PDF

New Generation Vaccines

  1. 1,040 pages
  2. English
  3. PDF
  4. Available on iOS & Android
eBook - PDF

New Generation Vaccines

Book details
Table of contents
Citations

About This Book

Highlighting the latest activities and initiatives of prominent organizations working in the vaccine industry such as the Bill and Melinda Gates Foundation, The Global Alliance for Vaccines and Immunization, WHO, UNICEF, the World Bank, New Generation Vaccines, Fourth Edition, details steps developing countries have taken toward research, development, manufacture, and regulation of several new vaccines for widespread use.

This text will:

cover the current state-of-the-art techniques in vaccine development – including the successes and the failures
trace vaccine development from the bench to public health with regard to both FDA and European Union regulations
investigate improved methods for immunizing large populations, and the use of needless vaccinations
discuss the advancements in the heavily government-funded areas for developing vaccines against potential bioterror and infectious disease agents as well as the immunization of large population bases for diseases like: Anthrax, Smallpox, Ebola, West Nile, SARS, and others
Updated throughout with new cutting-edge information on recent breakthroughs and developments.

NEW TO GENERATION VACCINES, FOURTH EDITION:

highlights the latest activities of prominent organizations in the vaccine industry
covers the current techniques in vaccine development
investigates improved methods for immunizing large populations

Frequently asked questions

Simply head over to the account section in settings and click on “Cancel Subscription” - it’s as simple as that. After you cancel, your membership will stay active for the remainder of the time you’ve paid for. Learn more here.
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
Both plans give you full access to the library and all of Perlego’s features. The only differences are the price and subscription period: With the annual plan you’ll save around 30% compared to 12 months on the monthly plan.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes, you can access New Generation Vaccines by Myrone M. Levine, Myron M. Levine, Gordon Dougan, Michael F. Good, Margaret A. Liu, Gary J. Nabel, James P. Nataro, Rino Rappuoli, Myrone M. Levine, Myron M. Levine, Gordon Dougan, Michael F. Good, Gary J. Nabel, James P. Nataro, Rino Rappuoli in PDF and/or ePUB format, as well as other popular books in Médecine & Médecine clinique. We have over one million books available in our catalogue for you to explore.

Information

Publisher
CRC Press
Year
2016
ISBN
9781420060744
Edition
4
Topic
Médecine
Subtopic
Médecine clinique

Table of contents

  1. Front Cover
  2. Foreword
  3. Preface
  4. Contents
  5. Contributors
  6. Chapter 1. Vaccines and Vaccination in Historical Perspective
  7. Chapter 2. Developing Vaccines in the Era of Reverse Vaccinology
  8. Chapter 3. Initial Clinical Evaluation of New Vaccine Candidates
  9. Chapter 4. Special Issues in Performing Vaccine Trials in Developing Countries
  10. Chapter 5. Long-Term Evaluation of Vaccine Performance: Methodological Issues for Phase III and Phase IV Studies
  11. Chapter 6. Ethical Considerations in the Conduct of Vaccine Trials in Developing Countries
  12. Chapter 7. Vaccine Economics: Assuring That Vaccines Are Developed for and Available in Developing Countries
  13. Chapter 8. Development and Supply of Vaccines: An Industry Perspective
  14. Chapter 9. Reaching Every Child: Achieving Equity in Global Immunization
  15. Chapter 10. A Paradigm for International Cooperation: The GAVI Alliance
  16. Chapter 11. Economic Analyses of Vaccines and Vaccination Programs
  17. Chapter 12. An Overview of U.S. Food and Drug Administration Licensure of Vaccines
  18. Chapter 13. Assuring Vaccine Quality by Strengthening Regulatory Agencies: The Work of the World Health Organization
  19. Chapter 14. Vaccine Safety
  20. Chapter 15. Manufacturing of Vaccines
  21. Chapter 16. Polio Eradication: Ongoing Innovation to End an Ancient Scourge
  22. Chapter 17. Recent Advances in Immunology That Impact Vaccine Development
  23. Chapter 18. Modulting Vaccine Responses with Innate Immunity
  24. Chapter 19. Immunodominance, Deveptive Imprinting, and Immune Refocusing Technology
  25. Chapter 20. Standardization and High-Throughput Measurement of T-Cell Responses to Vaccines
  26. Chapter 21. Transition to High-Throughput Laboratory Assays to Evaluate Multivalent Vaccines
  27. Chapter 22. The Challenge of Vaccine Protection in Very Young Infants
  28. Chapter 23. The Challenge of Inducing Vaccine Protection in the Elderly
  29. Chapter 24. Vaccination and Autoimmunity
  30. Chapter 25. Adjuvants for the Future
  31. Chapter 26. TLF9 Agonists for Immune Enhancement of Vaccines
  32. Chapter 27. Use of Genetically or Chemically Detoxified Mutants of Cholera and Escherichia coli Heat-Labile Enterotoxins as Mucosal Adjuvants
  33. Chapter 28. Recent Developments in Nonliving Antigen Delivery Systems
  34. Chapter 29. Virus-Like Particles as Vaccines and Vaccine Delivery Systems
  35. Chapter 30. Subunit Vaccines Produced Using Plant Biotechnology
  36. Chapter 31. Lipopeptide-Based Vaccines
  37. Chapter 32. Vaccines Based on Dendritic Cell Biology
  38. Chapter 33. Vaccinia Virus and Other Poxviruses as Live Vectors
  39. Chapter 34. Replication-Defective and Competent Adenovirus Recombinants as Vaccine Vectors
  40. Chapter 35. RNA Virus Replicon Vaccines
  41. Chapter 36. Engineering of Attenuated Salmonella enterica Serovars for Use as Live Vector Vaccines
  42. Chapter 37. DNA Vaccines
  43. Chapter 38. Overview of Heterologous Prime-Boost Immunization Strategies
  44. Chapter 39. Mucosal Immunization and Needle-Free Injection Devices
  45. Chapter 40. Advances in Transcutaneous Vaccine Delivery
  46. Chapter 41. Rationalizing Childhood Immunization Programs: The Variation in Schedules and Use of Combination Vaccines
  47. Chapter 42. Meningococcal Conjugate and Protein-Based Vaccines
  48. Chapter 43. Post-Licensure Impact of Haemophilus influenzae Type b and Serogroup C Neisseria meningitidis Conjugate Vaccines in Industrialized Countries
  49. Chapter 44. Haemophilus influenzae Type b Disease Burden and the Impact of Programmatic Infant Immunization in Developing Countries
  50. Chapter 45. Pneumococcal Protein-Polysaccharide Conjugate Vaccines
  51. Chapter 46. Pneumococcal Common Proteins and Other Vaccine Strategies
  52. Chapter 47. Polysaccharide-Based Conjugate Vaccines for Enteric Bacterial Infections: Typhoid Fever, Nontyphoidal Salmonellosis, and Escherichia coli O157:H7
  53. Chapter 48. Attenuated Strains of Salmonella enterica Serovars Typhi and Paratyphi as Live Oral Vaccines Against Enteric Fever
  54. Chapter 49. Oral Cholera Vaccines
  55. Chapter 50. Novel Vaccines Against Tuberculosis
  56. Chapter 51. Influenza
  57. Chapter 52. Chimeric Vaccines Against Japanese Encephalitis, Dengue, and West Nile
  58. Chapter 53. Vaccines Against Rotavirus Gastroenteritis
  59. Chapter 54. Novel Strategies for Immunizing Infants in Developing Countries Who Are Too Young to Receive the Currently Licensed Measles Vaccines
  60. Chapter 55. Challenges and Prospects for the Development of an HIV Vaccine
  61. Chapter 56. Vaccine Strategies to Prevent Dengue
  62. Chapter 57. Vaccination Against the Hepatitis C Virus
  63. Chapter 58. Vaccines Against Respiratory Syncytial Virus and Parainfluenza Viruses
  64. Chapter 59. Cytomegalovirus Vaccines
  65. Chapter 60. Epstein-Barr Virus Vaccines
  66. Chapter 61. Herpes Simplex Vaccines
  67. Chapter 62. Development of Vaccines to Prevent Group A Streptococcal Infections and Rheumatic Fever
  68. Chapter 63. Vaccines Against Group B Streptococcus
  69. Chapter 64. Overview of Live and Subcellular Vaccine Strategies Against Shigella
  70. Chapter 65. Vaccines Against Enterotoxigenic Escherichia coli
  71. Chapter 66. Multivalent Shigella Enterotoxigenic Escherichia coli Vaccine
  72. Chapter 67. Vaccines for Staphylococcus aureus Infections
  73. Chapter 68. Chlamydia trachomatis Vaccines
  74. Chapter 69. Malaria Vaccines in Clinical Development: Introduction and Recombinant/Subunit Approaches
  75. Chapter 70. Gene-Based Malaria Vaccines
  76. Chapter 71. Pre-erythrocytic and Asexual Erythrocytic Stage Whole-Organism Malaria Vaccines
  77. Chapter 72. Vaccines Against Leishmania
  78. Chapter 73. Vaccines Against Schistosomiasis
  79. Chapter 74. Vaccines Against Entamoeba histolytica
  80. Chapter 75. Hookworm Vaccines
  81. Chapter 76. Improved Smallpox Vaccines
  82. Chapter 77. Anthrax Vaccines
  83. Chapter 78. Tularemia Vaccines
  84. Chapter 79. Vaccines Against Plague
  85. Chapter 80. Development of Vaccines for Ebola and Marburg Viruses: Efficacy and Regulatory Considerations
  86. Chapter 81. Therapeutics and Vaccines Against Hendra and Nipah Viruses
  87. Chapter 82. Vaccines Against Lassa Fever
  88. Chapter 83. Hantavirus Vaccines
  89. Chapter 84. SARS Vaccines
  90. Chapter 85. Cancer-Specific Vaccines
  91. Chapter 86. Vaccines Against Human Papillomaviruses
  92. Chapter 87. Vaccines Against Alzheimer's and Other Neurodegenerative Diseases
  93. Chapter 88. Vaccination for Autoimmune and Other Chronic Inflammatory Disorders
  94. Chapter 89. Immunotherapies To Treat Drug Addiction
  95. Index
  96. Back Cover